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Abstract
Mantle Cell Lymphoma (MCL) is a well-known histological and clinical subtype of B-cell non-
Hodgkin's Lymphomas. It is usually characterized by an aggressive disease course, presenting with
advanced stage disease at diagnosis and with low response rates to therapy. However few cases of
indolent course MCL have been described. We herein report a case of MCL with splenomegaly and
peripheral blood involvement as main clinical features. The patient underwent moderate dose
splenic radiation therapy and achieved spleen downsizing and peripheral blood complete remission.
Splenic irradiation has been extensively used in the past as palliative treatment in several
lymphoproliferative disorders and a systemic effect and sometimes peripheral blood complete
remissions have been observed. Mainly advocated mechanisms responsible for this phenomenon
are considered direct radiation-induced apoptotic cell death, immune modulation via proportional
changes of lymphocyte subsets due to known differences in intrinsic radiosensitivity and a radiation-
induced cytokine release. The peculiar intrinsic radiosensitivity pattern of lymphoid cells could
probably be explained by well-defined individual genetic and molecular features. In this context,
among NHLs, MCL subtype has the highest rate of ATM (Ataxia Teleangiectasia Mutated)
inactivation. While the ATM gene is thought to play a key-role in detecting radiation-induced DNA
damage (expecially Double Strand Breaks), recent in vitro data support the hypothesis that ATM
loss may actually contribute to the radiosensitivity of MCL cells. ATM status was retrospectively
investigated in our patient, with the tool of Fluorescence In Situ Hybridization, showing a complete
inactivation of a single ATM allele secondary to the deletion of chromosomal region 11q22-23. The
presence of this kind of cytogenetic aberration may be regarded in the future as a potential
predictive marker of radiation response.
Full text
Mantle-Cell Lymphoma (MCL) has been clearly recog-
nized as a distinct histological and clinical subtype of B-
cell non-Hodgkin's Lymphomas. Typical of the elderly, it
has an estimated incidence of 2–3/100,000/year and
accounts for 8% of all NHLs [1]. Diagnostic work-up usu-
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with spleen enlargement, bone marrow and peripheral
blood involvement [2]. Important clinical prognostic fac-
tors are poor PS, splenomegaly, anemia and age [3]. While
MCL is generally considered an aggressive disease, with
median survivals of 2–3 years, few cases with a fairly indo-
lent disease course are described in the medical literature
[4]. We herein report the case of a 90 years-old female
referred to our institution hospital, with a history of active
phase chronic C-Hepatitis and a 4-yrs established diagno-
sis of MCL, made upon bone marrow biopsy. The speci-
men examination demonstrated a nodular pattern of
cleaved and small to medium sized cells without residual
germinal centres and with loosely structured meshwork of
follicular dendritic cells. Immunohistochemistry findings
on bone marrow at diagnosis were as follows: CCND1 +,
CD 5 +, CD 19 +, CD 20 +, CD 22 +, CD 3 - CD 10 -, CD
23 -, HLA DR +, Surface Membrane IgM-D/K. Flow
Cytometry revealed a dual stained population CD5+/
CD19 +, CD20+/CD 23 -, CD19 +/CD10 -, FMC7 +. Tak-
ing into account those data, expecially CCND1 positivity,
we reasonably thought to deal with MCL, instead of other
B-cell indolent lymphoproliferative disorders such as
Splenic Marginal Zone Lymphoma/Splenic Lymphoma
with Villous Lymphocytes. Clinically, her disease course
was characterized by a modest splenomegaly, with periph-
eral blood involvement with marked leucocytosis and
lack of lymph node enlargement, and therefore she was
repeatedly treated with single-agent chemotherapy (Chlo-
rambucil) with spleen downsizing and normalization of
WBC values. At the time of our observation she com-
plained of abdominal pain, anorexia and progressive
weight loss. ECOG PS was 1 to 2. Total Body CT scans
revealed a massive splenomegaly (25 cm in diameter)
without lymph nodes more than 1 cm in diameter at any
site. A modest hepatomegaly was also present. CBC
resulted as follows: WBC 30.000/mm3 (75 % lymph; 20 %
ANC); Hb 12,3 g/dl ; HCT 39 %; PLTs 60.000/mm3.
In order to obtain symptomatic relief, we considered radi-
ation therapy and chose to treat the whole spleen to a total
dose of 15 Gy in 10 fractions during 2 weeks time, with 6
MV Photons and anterior-posterior parallel opposite
fields. Radiation treatment was very well tolerated, with-
out recordable acute toxicity. At clinical and radiological
evaluation 3 weeks after RT, complete pain relief was
achieved, with reduction in spleen diameter (18 cm at
U.S. examination) and, surprisingly (even if already
reported), a peripheral blood complete remission. CBC
showed: WBC 2100/mm3; (ANC 67 %; 19 % Lymph); Hb
12,1 g/dl; HCT 37 %; PLT 61.000/mm3. Circulating
malignant lymphoid cells were absent at peripheral blood
smears and at Flow Cytometry examination. A second
bone marrow biopsy was not performed due to patient's
age and PS. The latest follow-up performed one year after
radiotherapy showed a continuous unmaintained com-
plete peripheral response.
Splenic Irradiation (SI) has been extensively used in the
past as palliative treatment in several haematological
malignancies such as chronic myeloproliferative disorders
[chronic myelogenous leukaemia (CML), essential throm-
bocythemia (ET), polycythemia vera (PV) and agnostic
myeloid metaplasia (AMM)], chronic lymphoprolifera-
tive disorders [chronic lymphocytic leukaemia (CLL), pro-
lymphocytic leukaemia (PLL), hairy cell leukaemia (HCL)
and splenic marginal zone lymphoma (SMZL)] and even
acute myelogenous leukemia [5-11]. Previously reported
high response rates could be explained by different mech-
anisms of action, but the main event is thought to be a
direct radiation-induced apoptotic cell death that leads to
the elimination of malignant cells located in the spleen
(since lymphocytes undergo radiation-induced apoptosis
even at very low doses)[12]. A systemic effect and some-
times peripheral blood and even bone marrow complete
remissions (CRs) have been observed in several clinical
situations [5,13-15], most frequently CLL, PLL and HCL.
To our knowledge, no Crs are described during myelopro-
liferative disorders. Different doses and fraction sizes have
been delivered (daily, weekly, three times a week sched-
ules with doses ranging mostly from 5 Gy to 15 Gy). Any-
way, the arising question appears to be how SI could clear
the bone marrow, removing MCL clones. Several biologi-
cal mechanisms have been hypothesized by different
authors to explain this effect [5]. At first, a direct radiation-
induced killing of splenic neoplastic cells has been men-
tioned, acting through the clearance of a potential source
of circulating lymphoma cells [16]. Secondly, an immune
modulation via proportional changes of lymphocyte sub-
sets has been advocated as a key event: in this case the dif-
ferential cell killing of normal lymphocytes (due to
known differences in intrinsic radiosensitivity) is believed
to cause a redistribution of circulating lymphoid subpop-
ulations with subsequent reduction of normal T-suppres-
sor lymphocytes and increased anti-tumour activity
[17,18]. Thirdly, a radiation-induced release of cytokines,
such as TNFα or IL-2, is believed to potentially stimulate
a secondary immune modulation, enhancing anti-neo-
plastic cell-mediated effects [19]. In this context, another
radiation-induced cell killing mechanism to be consid-
ered is the so-called "bystander effect", well described in
several experimental studies and anecdotal clinical find-
ings: this phenomenon consists of a biological response
of unirradiated neighbours or distant cells after target cells
irradiation. When considering distant effects produced by
local radiation therapy, it is also known as 'abscopal
effect' [20,21]. This event seems to be particularly signifi-
cant after radiation exposure at low doses and has been
advocated to play some kind of role in radiation-inducedPage 2 of 3
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induced bystander tumor cells killing [22].
The peculiar intrinsic radiosensitivity pattern of lymphoid
cells and the above briefly mentioned mechanisms could
probably explain the known radiation response pheno-
type of many lymphoproliferative disorders, but more
individual genetic and molecular features could certainly
offer more details about some unusual responses of spe-
cific patients. Among NHLs, MCL subtype has the highest
rate of ATM (Ataxia Teleangiectasia Mutated) inactivation,
due to the presence of deletions or mutations in up to 40–
50% of patients [23-25]. The ATM gene is thought to play
a key-role in detecting radiation-induced DNA damage
(expecially Double Strand Breaks) and it is known to be
affected by germline mutations (truncation) in patients
with Ataxia Teleangiectasia, an autosomal recessive dis-
ease characterized by cerebellar ataxia, immunodefi-
ciency, predisposition to lymphoproliferative
malignancies and a highly increased sensitivity to ionizing
radiations. MCL patients bearing ATM inactivation seem
not to have a worse prognosis, while recent in vitro data
suggest that ATM loss may actually contribute to radiosen-
sitivity of MCL cells [26]. ATM status was retrospectively
investigated in our patient, with the tool of Fluorescence
In Situ Hybridization (FISH) on bone marrow biopsy at
diagnosis, showing a complete inactivation of a single
ATM allele secondary to a deletion of chromosomal
region 11q22-23. We suggest that the presence of this kind
of cytogenetic aberration, recently reported [27], could be
considered as one of the possible explanations of high
radiosensitivity profiles of some MCLs, and be regarded in
the future as a potential predictive marker of response.
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